Diagnostyka stock
Price history
−14.40% over the period1 year: from zł 176.40 (November 20, 2025) to zł 151.00 (November 20, 2026), −14.40%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | zł 151.00 |
| October 30, 2026 | zł 148.40 |
| September 30, 2026 | zł 160.70 |
| August 31, 2026 | zł 168.90 |
| July 31, 2026 | zł 166.60 |
| June 30, 2026 | zł 173.70 |
| May 29, 2026 | zł 177.90 |
| April 30, 2026 | zł 152.00 |
| March 31, 2026 | zł 171.40 |
| February 27, 2026 | zł 188.65 |
| January 30, 2026 | zł 189.75 |
| December 30, 2025 | zł 171.00 |
| November 28, 2025 | zł 170.55 |
| November 20, 2025 | zł 176.40 |
At a glance
The company
Polish medical laboratory providing diagnostic services including ultrasound, X-ray, CT scans, MRI, and specialized microbiology and molecular biology testing
Latest results
Quarter to June 30, 2026 · EPS zł 1.70
Next event
TickerLandia's take on Diagnostyka
- Cheaper than similar companies: trailing 12-month P/E 20 vs 29 (−29%) in a group of 10.
- Strong point: Earnings stability (76/100 in its group). Weak point: Market momentum (21/100).
- “Most upside for analysts” (Poland): No. 7 of 23.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−27.40% from the 52-week high
Analysts · 7 analysts
Average targetzł 191.39+26.75% vs. price
Buy 4 · Hold 3 · Sell 0
TickerLandia Fingerprint: Diagnostyka
Compared with similar companies: weak momentum, high earnings stability, and low financial strength.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow29
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 10.3 14 P/E (trailing 12 months) 20.2 15 Forward P/E 15.6 14 Price/book 10.1 83 Price/sales 1.99 20 Profitabilityhigh72
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 78.6% 98 Net margin 9.9% 54 ROE 55.4% 87 ROA 11.8% 83 Operating margin 14.9% 39 Earnings stabilityhigh76
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.3% 91 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthaverage56
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +18.86% 80 Earnings growth (year over year) −10.10% 10 Revenue growth (year over year) +16.10% 80 Financial strengthlow26
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 5.60 37 Net debt/EBITDAcounts in reverse: lower means more financial strength 1.81 58 Debt/equitycounts in reverse: lower means more financial strength 2.32 9 Current ratio 0.82 2 Dividendaverage57
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 2 years 15 Payout ratio 58.3% 72 Dividend yield 2.9% 83 Market momentumweak21
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average −9.46% 26 1-year return −14.40% 16 Riskaverage45
How much the price swings.
Metric Value Position in group Volatility (60 days) 22.4% 28 Maximum drawdown (12 months) 27.9% 62
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Diagnostyka is cheaper than similar companies
Diagnostyka's P/E (trailing 12 months): 20.2, −29% against the median of a group of 10 similar companies (28.6).
Compared with 10 similar companies
| Metric | Diagnostyka | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 20.2 | Low | |
| Forward P/E | 15.6 | Low | |
| Operating margin | 14.9% | Middle | |
| ROE | 55.4% | High | |
| Debt/equity | 2.32 | High |
Grey band: the middle half of the group; tick: the median; dot: Diagnostyka. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
zł 683.02M
Latest quarter · Q2 2026
Net income
zł 57.39M
Latest quarter · Q2 2026
Quarterly net margin
8.4%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- zł 5.14B
- P/E
- 20.2
- EPS
- zł 7.55
- Volume
- 38.33K
- Daily trading
- €1.11M
- Dividend yield
- 2.91%
- Last ex-dividend on June 1, 2026
How Diagnostyka is changing
All resultsRevenue grew 18.9% a year on average over the last 3 years
Operating margin fell from 17.6% to 15.9%
Profits turn into cash: free cash flow equal to 148% of net income
Returns
Diagnostyka returns with dividends
zł 1,000 invested in Diagnostyka 1 year ago, on November 20, 2025, would be worth zł 878 today with dividends reinvested: −12.22% in total, −12.22% per year. On price alone it would be zł 856 (−14.40%).
| Period | Diagnostyka | zł 1,000 becomes |
|---|---|---|
| 1 month | −2.58% | zł 974 |
| 6 months | −6.62% | zł 934 |
| Year to date | −11.70% | zł 883 |
| 1 year | −12.22% | zł 878 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Diagnostyka: technical analysis
Diagnostyka is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 30.3% below its all-time closing high (zł 216.70, September 12, 2025).
- Trend
- Downward
- RSI (14 sessions)
- 45
- Between 30 and 70
- vs 200-session average
- −9.46%
Support and resistance
Price areas where Diagnostyka has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancezł 160.00+5.96%2 touches, last on October 13, 2026
- Resistancezł 157.82+4.52%2 touches, last on October 1, 2026
- Resistancezł 155.07+2.69%3 touches, last on October 9, 2026
- Last pricezł 151.00
- No support below: the price is near the lows of the year
Volatility and risk
- Volatility (60 sessions, annualised)
- 22.4%
- Largest fall in the last year
- −27.89%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Diagnostyka and its competitors
Based in Kraków, Diagnostyka S.A. has been active since 1998 as a medical laboratory serving clients across Poland. Its offer combines imaging procedures, namely magnetic resonance imaging, computed tomography, X-ray and ultrasound, with specialised laboratory research in microbiology, autoimmunity, toxicology and molecular biology. The company also carries out human genome research, histopathological and cytological examinations, immunohistochemical tests and cytogenetic tests. Its customers are individual clients as well as public and private entities. Its activities are concentrated in Poland.
- Headquarters
- Kraków, Poland
- Employees
- 8,645
- Founded
- 1998
- Chief executive
- Jakub Swadzba
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| DiagnostykaDIA | $1.27B | 14.9% | 20.2 | −6.62% |
| DiaSorinDIA | $4.21B | 22.3% | 28.6 | +14.88% |
| QiagenQIA | $10.23B | 26.7% | 28.5 | +50.69% |
| bioMérieuxBIM | $11.82B | 16.0% | 23.4 | +25.67% |
| Eurofins ScientificERF | $16.03B | 14.1% | 29.6 | +37.31% |
| Lonza GroupLONN | $54.2B | 23.5% | 43.2 | +32.22% |
Same industry or related industries, similar size. Compare Diagnostyka with its competitors · Full profile